Navigation Links
Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
Date:2/7/2008

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that data from the Phase II trial of its novel secretory phospholipaseA2 inhibitor Varespladib (A-002) for the treatment of coronary heart disease will be presented as a late breaker at the 2008 American College of Cardiology 57th Annual Scientific Session on Monday, March 31, 2008 in Chicago, Illinois.

The Phase II trial known as PLASMA (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo-controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint was a reduction in secretory phospholipase A2 (sPLA2). The study also evaluated the effect of Varespladib on cholesterol levels (LDL-C, non-HDL and total cholesterol) as well as inflammation in patients with stable coronary heart disease.

PLASMA Late-Breaker Trial Data Presentation:

Date/Time: Monday, March 31 from 2:30-2:45pm.

Title/Author: Effects of a Selective Inhibitor of Secretory

Phospholipase A2 on Low Density Lipoproteins and Inflammatory Pathways,

Robert S. Rosenson, MD, Director, Lipoprotein Disorders and Clinical

Atherosclerosis Research, Division of Cardiovascular Medicine at the

University of Michigan, for the PLASMA Investigators.

Location: McCormick Place, Vista Room S406

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and a
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
3. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
4. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
5. Toxoplasma infection increases risk of schizophrenia, study suggests
6. New Heart Pump Shows Promise in Trial
7. Trial to Test Gene Therapy for Angina in Women
8. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
9. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. MDS Pharma Services Wins Award for Management of Global Malaria Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 At this moment, Ebola is causing ... eliminate the root cause of the virus and other problems ... the nonprofit organization Books For Africa to provide copies of ... Can Live the Life of Their Dreams, to those who ... Africans with the tools they need to make the leap ...
(Date:8/20/2014)... Va. (PRWEB) August 20, 2014 Riverside ... William Dameron , who joined its Warsaw Medical Arts ... physician specialized in Family Medicine, is accepting new patients. ... School of Medicine, completed his residency at the Mountain ... back to Virginia. , “I really like the rural ...
(Date:8/19/2014)... The elegant bamboo floorings from BambooIndustry.com are tough ... an environmentally conscious way with the company’s floorings. All ... an aluminum oxide finish to help resist wear and ... , Recently, the company has released its new assortment ... fresh items are specially made for global customers. They ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Midtown Dentistry in ... amalgam-free dental office. All patients with cavities, or with ... latest white fillings that can safely repair and restore teeth. ... the very latest materials, all of which are completely amalgam ... safe for use by the FDA for adults and children ...
(Date:8/19/2014)... Petersburg, FL (PRWEB) August 20, 2014 What ... skin care? What can soften skin, replenish and nourish it ... from Sublime Beauty®. , "Client after client raves about how ... says Kathy Heshelow, founder of Sublime Beauty®. "The ingredients ... easy to use. Simply smooth it over cleansed skin ...
Breaking Medicine News(10 mins):Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:BambooIndustry.com Announces Up To 30% Discount On Its New Click Strand Woven Bamboo Floorings 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2Health News:That "Something Special" to Improve Skin Takes Only 10 Minutes Per Week; on Sale at Sublime Beauty® 2
... interest in cancer research careers among the next generation ... for 10 undergraduate students to experience the field first ... J. Bardos Science Education Awards for Undergraduate Students. , ... the students by providing financial support to travel to ...
... been is,a leader in serving people who are visually impaired ... People who are legally blind can function and lead ... training., The news that Lt. Gov. Paterson will become ... that people with vision loss can,achieve great heights., As ...
... profit up 138% ... growth, OWINGS MILLS, Md., March 12 Medifast, Inc.,(NYSE: ... year ended December 31, 2007., Financial highlights included:, ... increased 29% compared to the previous year,s ...
... who live with,diabetes on a daily basis are ... and if necessary, take medication. What many may,not ... healthy insulin levels,may lead to unexpected events at ... November/December 2007 issue of General Dentistry, the AGD,s,clinical, ...
... Researchers think it,s likely woman was first infected with dangerous ... share their homes, their food and more with their pets, ... with your animals is a drug-resistant staph infection. , However, ... the New England Journal of Medicine , a German ...
... index monitoring to standard methods found little difference ... much-touted technology designed to detect when patients are ... appear to work any better than standard methods. ... lower the incidence of "anesthesia awareness" in a ...
Cached Medicine News:Health News:AACR-Bardos Awards for Undergraduate Students announced 2Health News:Medifast Announces Year-end 2007 Financial Results 2Health News:Medifast Announces Year-end 2007 Financial Results 3Health News:Medifast Announces Year-end 2007 Financial Results 4Health News:Medifast Announces Year-end 2007 Financial Results 5Health News:Medifast Announces Year-end 2007 Financial Results 6Health News:Medifast Announces Year-end 2007 Financial Results 7Health News:Medifast Announces Year-end 2007 Financial Results 8Health News:Medifast Announces Year-end 2007 Financial Results 9Health News:Medications Plus Dental Materials May Equal Infection for Diabetic Patients 2Health News:Woman and Cat Shared 'Super Bug' 2Health News:Woman and Cat Shared 'Super Bug' 3Health News:New Technology No Better at Spotting 'Anesthesia Awareness' 2Health News:New Technology No Better at Spotting 'Anesthesia Awareness' 3
(Date:8/19/2014)... 2014  Tokyo-based Atonarp Inc. announced today $8 ... by Walden Riverwood Ventures with participation from other ... Smart Spectrometer technology platform, which will enable a ... the oil & gas and healthcare industries for ... to partner with Atonarp in pursuing the commercialization ...
(Date:8/19/2014)... 19, 2014  Boehringer Ingelheim today announced that ... for review the New Drug Application (NDA) for ... delivered via the Respimat ® inhaler for ... of airflow obstruction in patients with chronic obstructive ... Tiotropium + olodaterol FDC will not be indicated ...
(Date:8/19/2014)... Aug. 19, 2014  Cardiva Medical, Inc. announced today ... a $16.5 million Series 3 private equity financing and ... The Company will use the proceeds of the Series ... commercial efforts for its VASCADE® Vascular Closure System in ... Investing in Series 3 private equity financing was ...
Breaking Medicine Technology:Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
... ACULAR® ophthalmic solution is a prescription ... instruct you to use after your ... eyes and may cause them to ... symptoms of inflammation include redness and ...
... solution is a prescription eye drop ... to use after your cataract surgery. ... may cause them to become inflamed. ... inflammation include redness and swelling. If ...
... ECG-9320 is a full-featured ECG ... IEC60601-2-51 new international standard for ... digital filter performance. The ECG ... managed on a Windows PC ...
Mid-level interpretive resting ECG...
Medicine Products: